- Home
- APA vs BMRN Comparison
APA vs BMRN Comparison
Compare APA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APA | BMRN |
|---|---|---|
| Founded | 1954 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 12.3B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | APA | BMRN |
|---|---|---|
| Price | $42.81 | $60.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 18 |
| Target Price | $31.96 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 5.0M | 1.7M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ 75.77 | N/A |
| EPS | ★ 3.37 | 0.77 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $3.86 | $15.02 |
| Revenue Next Year | N/A | $12.23 |
| P/E Ratio | ★ $12.96 | $79.68 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $21.64 | $49.26 |
| 52 Week High | $47.44 | $70.98 |
Technical Indicators
Market Signals| Indicator | APA | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 33.65 |
| Support Level | $33.27 | $58.03 |
| Resistance Level | $45.36 | $60.99 |
| Average True Range (ATR) | 1.38 | 1.54 |
| MACD | -0.45 | -0.63 |
| Stochastic Oscillator | 13.24 | 3.61 |
Price Performance
Historical ComparisonAbout APA APA Corporation
APA Corp is an independent exploration and production company. It develops and produces crude oil, natural gas, and natural gas liquids. The company's business has oil and gas operations in four segments: Egypt, the North Sea, Suriname, and the U.S. The company generates the majority of its revenue from the U.S. reporting segment. The company also has exploration interests in Uruguay, Alaska, and other international locations.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.